Tim Mayall

Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study

Marc Gurwith, Michael Lock, Eve M. Taylor et al. · The Lancet Infectious Diseases · 2013 · 154 citations · Full text

Veterinary Medicine, Immunology, Infectious Diseases +16

Pre-Clinical Evaluation of a Replication-Competent Recombinant Adenovirus Serotype 4 Vaccine Expressing Influenza H5 Hemagglutinin

Jeff Alexander, Simone Visosky Ward, Jason Mendy et al. · PLoS ONE · 2012 · 64 citations · Full text

Life Sciences, Immunology, Infectious Diseases +17

Pre-Clinical Development of a Recombinant, Replication-Competent Adenovirus Serotype 4 Vector Vaccine Expressing HIV-1 Envelope 1086 Clade C

Jeff Alexander, Jason Mendy, Lo Vang et al. · PLoS ONE · 2013 · 28 citations · Full text

Life Sciences, Infectious Diseases, Molecular Biology +17